Tuberculosis Infection Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • PuriflOH’s Free Radical Generator deemed to be successful in a real world environment for curing tuberculosis
  • Trials have been moved from the Government Chest Hospital in Hyderabad to the Bhaskar Medical College and Hospital due to unsuitable conditions

PuriflOH Limited has provided the first stage report of tuberculosis trials completed at the Government Chest Hospital in Hyderabad.

Dr Anil has reported on the protocols and outcomes from the testing of PuriflOH’s Free Radical Generator (FRG) air purification system for the elimination of tuberculosis.

Tuberculosis is an infectious disease which damages lungs, and other parts of the body, and can cause serious illness and even death. It is caused by the bacterium mycobacterium tuberculosis (MTB).

Most patients with TB do not have symptoms and their bodies are able to fight them off, this is known as inactive TB and is not infectious or deadly. Those who aren’t able to fight off the bacteria are said to have active TB and they are infectious.

Currently, the only way to eliminate TB is through the use of special antibiotics which must be taken for at least six months. In some extreme cases patients are required to stay in hospital until it has all been eliminated.

The generator has the ability to generate a range of ‘free radicals,’ uncharged molecules, which are able to eliminate a wide range of contaminants such as hydrocarbons, bacteria, toxins, moulds and viruses.

The output can be engineered to produce ranges and combinations of the radicals to cater to the specific requirement. The most powerful is the OH radical which is extremely effective in purifying water and disinfecting surfaces and environments.

The environment for the first trial was in a dedicated ward for respiratory diseases that was large and open to outside air. However, the environment was complex and it proved difficult to determine initial TB levels.

Results from the first phase of testing reinforced the confidence the FRG will be effective in reducing airborne bacteria levels with the second stage of testing already commencing.

Some issues identified during the testing included: the patients weren’t releasing significant levels of MTB into the environment, the ward had a great deal of air flow due to a high rate of ventilation and the ward was too large for the planned treatment.

While changes to the trial were undertaken the environment was ultimately deemed unsuitable to accurately provide the desired outcomes.

The trials have moved to the Bhaskar Medical College and Hospital and discussions have been held to ensure the conditions are suitable for a successful trial.

PO3 by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.